TÜBINGEN, Germany and BOSTON, April 09, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced its participation in two upcoming investor conferences:

• Kempen Life Sciences Conference, April 16, 2019 in Amsterdam, Netherlands: The Company will host one-on-one meetings and CFO Pierre Kemula will give a corporate presentation at 11:30am CET.
• Solebury Trout Boston Private Company Showcase, April 18, 2019, in Boston, MA: The Company will host one-on-one meetings and Vice President, Investor Relations Matthew Beck will give a corporate presentation at 2:10pm ET.

Neither presentation will be webcast.

About CureVac AG
CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.

For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.

Investor Contact

Matthew Beck, Vice President Investor Relations
CureVac, Boston, MA, United States
T: +1 917-415-1750
matthew.beck@curevac.com